2022 Fiscal Year Final Research Report
Investigation for spontaneous regression of malignant lymphoma
| Project/Area Number |
21K16260
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 54010:Hematology and medical oncology-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2023-03-31
|
| Keywords | 免疫不全関連リンパ増殖症 / 悪性リンパ腫 |
|---|
| Outline of Final Research Achievements |
Some cases of immunodeficiency-associated lymphoproliferative disease (IA-LPD) may regress spontaneously, but the mechanism is not yet elucidated. We performed nucleic acid extraction from formalin-fixed paraffin-embedded tissues and gene expression analysis using a digital omics analyzer in 10 cases who developed malignant lymphoma during treatment of autoimmune diseases and 2 cases of LPD after solid organ transplantation (total 12 cases as ID group). Clustering analysis revealed 67 genes significantly differentially expressed in the ID group compared with the other 12 cases of follicular lymphoma, of which 47 genes with no histological differences among the ID group were considered to be possibly associated with the development of IA-LPD.
|
| Free Research Field |
血液内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
悪性リンパ腫には様々な組織型が存在し，概して化学療法や放射線治療に対する感受性が高いが，化学療法抵抗性を示す症例の予後は悪く，その治療開発は喫緊の課題となっている.
昨今，様々な分子標的薬が開発され臨床応用されているが，依然として予後不良なリンパ腫の予後改善には不十分である．腫瘍縮小を目標とする従来の分子標的薬と違い，自然退縮を誘導する遺伝子が治療標的となれば，治癒，長期寛解が期待できる可能性があると考えられる．
|
